CN1549718A - 化合物用于治疗由lasik和其它眼睛手术或创伤后角膜神经损伤而导致的情况的应用 - Google Patents

化合物用于治疗由lasik和其它眼睛手术或创伤后角膜神经损伤而导致的情况的应用 Download PDF

Info

Publication number
CN1549718A
CN1549718A CNA028168682A CN02816868A CN1549718A CN 1549718 A CN1549718 A CN 1549718A CN A028168682 A CNA028168682 A CN A028168682A CN 02816868 A CN02816868 A CN 02816868A CN 1549718 A CN1549718 A CN 1549718A
Authority
CN
China
Prior art keywords
people
chemical compound
corneal nerve
corneal
ait
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA028168682A
Other languages
English (en)
Chinese (zh)
Inventor
M・R・赫勒贝格
M·R·赫勒贝格
亚妮
彭玉豪
J·M·亚妮
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Alcon Universal Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Universal Ltd filed Critical Alcon Universal Ltd
Publication of CN1549718A publication Critical patent/CN1549718A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7012—Compounds having a free or esterified carboxyl group attached, directly or through a carbon chain, to a carbon atom of the saccharide radical, e.g. glucuronic acid, neuraminic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/08—Ethers or acetals acyclic, e.g. paraformaldehyde
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
CNA028168682A 2001-08-29 2002-07-23 化合物用于治疗由lasik和其它眼睛手术或创伤后角膜神经损伤而导致的情况的应用 Pending CN1549718A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31565201P 2001-08-29 2001-08-29
US60/315,652 2001-08-29

Publications (1)

Publication Number Publication Date
CN1549718A true CN1549718A (zh) 2004-11-24

Family

ID=23225436

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA028168682A Pending CN1549718A (zh) 2001-08-29 2002-07-23 化合物用于治疗由lasik和其它眼睛手术或创伤后角膜神经损伤而导致的情况的应用

Country Status (10)

Country Link
EP (1) EP1420791A4 (fr)
JP (1) JP2005502678A (fr)
CN (1) CN1549718A (fr)
AR (1) AR036194A1 (fr)
BR (1) BR0212151A (fr)
CA (1) CA2455896A1 (fr)
MX (1) MXPA04001255A (fr)
PL (1) PL368565A1 (fr)
WO (1) WO2003020281A1 (fr)
ZA (1) ZA200400837B (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004091662A1 (fr) * 2003-04-18 2004-10-28 Senju Pharmaceutical Co. Ltd. Agent pour la reparation de la perception corneenne
ES2234428B1 (es) * 2003-12-09 2006-11-01 Universidad Miguel Hernandez Compuestos para el tratamiento de la sequedad de la superficie ocular provocada por la cirugia fotorrefractiva.
CN1997381B (zh) * 2004-04-23 2011-06-08 千寿制药株式会社 含有pacap及其衍生物的角膜神经突形成促进剂
JP4932480B2 (ja) * 2004-06-03 2012-05-16 千寿製薬株式会社 アミド化合物を含有する角膜知覚回復剤
US20090082455A1 (en) 2005-03-15 2009-03-26 Ono Pharmaceutical Co. Lted Therapeutic agent for ophthalmic disease
CN113350326B (zh) * 2021-07-28 2023-03-17 爱尔眼科医院集团股份有限公司 化合物lm22b-10在制备角膜上皮及神经损伤治疗药物中的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5166317A (en) * 1988-10-31 1992-11-24 Houston Biotechnology Incorporated Neurotrophic factor
FR2672213B1 (fr) * 1991-02-05 1995-03-10 Sanofi Sa Utilisation de derives 4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridiniques comme capteurs de radicaux libres.
US5767079A (en) * 1992-07-08 1998-06-16 Celtrix Pharmaceuticals, Inc. Method of treating ophthalmic disorders using TGF -β
US5604244A (en) * 1995-06-07 1997-02-18 Alcon Laboratories, Inc. Intraocular irrigating solution containing a polyamine antagonist
TWI246421B (en) * 1998-12-03 2006-01-01 Alcon Mfg Ltd Use of neurotrophic factor stimulators for the treatment of ophthalmic neurodegenerative diseases
WO2001085152A2 (fr) * 2000-05-10 2001-11-15 Alcon, Inc. R-eliprodil applique au traitement du glaucome

Also Published As

Publication number Publication date
EP1420791A4 (fr) 2004-09-15
EP1420791A1 (fr) 2004-05-26
MXPA04001255A (es) 2004-05-27
ZA200400837B (en) 2005-02-02
AR036194A1 (es) 2004-08-18
JP2005502678A (ja) 2005-01-27
BR0212151A (pt) 2004-08-24
WO2003020281A1 (fr) 2003-03-13
CA2455896A1 (fr) 2003-03-13
PL368565A1 (en) 2005-04-04

Similar Documents

Publication Publication Date Title
JP5582535B2 (ja) 点眼投与による神経疾患または精神神経疾患の治療または予防
CN108135737A (zh) 用于治疗翼状胬肉的组合物和方法
CN109908140A (zh) 生物素治疗多发性硬化的用途
CN101048156A (zh) 用于治疗青光眼性视网膜病变及眼病的JunN端激酶抑制剂
CN1549718A (zh) 化合物用于治疗由lasik和其它眼睛手术或创伤后角膜神经损伤而导致的情况的应用
JP2016026229A (ja) Ｂｄｎｆ（脳由来神経栄養因子）をベースとする眼科用製剤およびそれらの使用
CN1325308A (zh) 使用神经营养因子刺激素治疗眼科神经退变性疾病
CN1302810C (zh) 含α1受体阻断剂作为活性成分的视神经保护药物
JP2014510115A (ja) 初期の緑内障における正常な視覚機能を回復するｐａｃａｐ（下垂体アデニル酸シクラーゼ活性化ポリペプチド）に基づく眼科用製剤
CN1870989A (zh) 用于治疗眼科疾病的香豆素衍生物
US20040162315A1 (en) Use of compounds for treating conditions resulting from injury to the corneal nerve after LASIK and other ocular surgeries or trauma
RU2134107C1 (ru) Препарат "гистохром" для лечения воспалительных заболеваний сетчатки и роговицы глаз
CN105935443A (zh) 一种治疗糖尿病性白内障的药物组合物
JP4268912B2 (ja) 薬物徐放性コンタクトレンズキット
CN1838955A (zh) 用于治疗视器的神经变性疾病及糖尿病的氟吡汀制剂
CN1049602C (zh) 治疗缺血性眼病的复方注射液
RU2224519C2 (ru) Антиоксидантное и стимулирующее рост нервных клеток средство
AU2002322700A1 (en) Use of compounds for treating conditions resulting from injury to the corneal nerve after lasik and other ocular surgeries or trauma
JP2004331502A (ja) 視神経細胞保護剤
KR20190099495A (ko) 안과용 제제
RU2733392C1 (ru) Комбинированное офтальмологическое средство
US6906077B1 (en) Use of neurotrophic factor stimulators for the treatment of ophthalmic neurodegenerative diseases
EP1169026B1 (fr) Utilisation d'activateurs ap-1 pour le traitement du glaucome et de l'hypertension oculaire
KR20240050324A (ko) 빈포세틴을 사용한 근시치료방법
MXPA01002895A (en) Use of neurotrophic factor stimulators for the treatment of ophthalmic neurodegenerative diseases

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication